Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings

9/24 Early, Late

Gasperetti et al., EP Europace, doi:10.1093/europace/euaa216 (Peer Reviewed)
Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings

Source PDF Share Tweet

Safety study of 649 patients finding that HCQ administration is safe for short-term treatment for patients with COVID-19 infection regardless of the clinical setting of delivery, causing only modest QTc prolongation and no directly attributable arrhythmic deaths.

Arrhythmic safety data from a large cohort of patients treated with HCQ alone or in combination with other QT-prolonging drugs.

Gasperetti et al., 9/24/2020, peer-reviewed, 23 authors.

All 344 studies Meta Analysis

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit